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osting by EAbstract Three sensitive methods were developed for simultaneous determination of Ezetimibe
(EZB) and Atorvastatin calcium (ATVC) in binary mixtures. First derivative (D1) spectrophotom-
etry was employed for simultaneous determination of EZB (223.8 nm) and ATVC (233.0 nm) with a
mean percentage recovery of 100.23 ± 1.62 and 99.58 ± 0.84, respectively. Linearity ranges were
10.00–30.00 lg mL1 and 10.00–35.00 lg mL1, respectively. Isosbestic point (IS) spectrophotom-
etry, in conjunction with second derivative (D2) spectrophotometry was employed for analysis of
the same mixture. Total concentration was determined at IS, 224.6 nm and 238.6 nm over a concen-
tration range of 10.00–35.00 lg mL1 and 5.00–30.00 lg mL1, respectively. ATVC concentration
was determined using D2 at 313.0 nm (10.00–35.00 lg mL1) with a mean recovery percentage of
99.72 ± 1.36, while EZB was determined mathematically at 224.6 nm (99.75 ± 1.43) and4 650 66 53.
.edu.eg (M.A. Al-Ghobashy).
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Fig. 1 Chemical structure of Ezet
calcium (b).
52 Y.Z. Baghdady et al.238.6 nm (99.80 ± 0.95). TLC-densitometry was employed for the determination of the same mix-
ture; 0.10–0.60 lg band1 for both drugs. Separation was carried out on silica gel plates using
diethyl ether–ethyl acetate (7:3 v/v). EZB and ATVC were resolved with Rf values of 0.78 and
0.13. Determination was carried out at 254.0 nm with a mean percentage recovery of
99.77 ± 1.30 and 99.86 ± 0.97, respectively. Methods were validated according to ICH guidelines
and successfully applied for analysis of bulk powder and pharmaceutical formulations. Results were
statistically compared to a reported method and no signiﬁcant difference was noticed regarding
accuracy and precision.
ª 2012 Cairo University. Production and hosting by Elsevier B.V. All rights reserved.Introduction
Ezetimibe (EZB) inhibits the absorption of cholesterol,
decreasing the delivery of intestinal cholesterol to the liver.
Atorvastatin calcium (ATVC) is a synthetic lipid-lowering
agent that inhibits ß-hydroxy-ß-methylglutaryl-coenzyme A
(HMG-CoA) reductase. Recently, a combination of EZB and
ATVC has been introduced to the market. The co-administra-
tion of both drugs offers a well-tolerated and highly efﬁcient
treatment option for patients with dyslipidemia and helps in
prescribing a low dose ATVC, which may reduce side effects
[1]. Chemically EZB is [(3R,4S)-1-(4-ﬂuorophenyl)-3-[(3S)-3-
(4-ﬂuorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-2-aze-
tidinone], and ATVC is [R-(R\,R\)]-2-(4-ﬂuorophenyl)-b,
d-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)car-
bonyl]-1H-pyrrole-1 – heptanoic acid – calcium salt (2:1) trihy-
drate [2]. The chemical structures of ATVC and EZB are shown
in Fig. 1.
A survey of the literature revealed the following analytical
techniques concerned with the determination of EZB/ATVC
mixture. Reported spectrophotometric methods for the simul-
taneous determination of EZB/ATVC mixture include simulta-
neous equation method [3–5], dual wavelength measurement
[6], absorbance ratio method [3,7], derivative ratio method
[8,9], H-point standard addition method [9], multi-wavelength
method [10] and differential spectrophotometry [9]. Other
methods include; HPTLC [5,11–13], HPLC [4,5,8,14–19].
With the rapid increase in the number of generics in local
markets, manufacturers tend to seek for reliable analysis pro-
tocols. Such methods should meet the strict requirements of lo-
cal regulatory authorities. Unfortunately, not all published
methods are reliable for this purpose. In many cases, they
are not properly validated and problems arise upon method
transfer to quality control labs. The aim of this work is theimibe (a) and Atorvastatindevelopment of orthogonal, simple, sensitive and validated
methods for the determination of EZB and ATVC in their bin-
ary mixtures and pharmaceutical preparations. Spectropho-
tometry and TLC-densitometry were trialled in order to
provide orthogonal results via analyse of the studied mixture
using different techniques.
Experimental
Instruments
A double beam UV–visible spectrophotometer model UV-
1650 PC (SHIMADZU, Japan) connected to IBM compatible
computer was used for all determinations. Hardware control
as well as data acquisition and treatment was carried out using
UV Probe software, version 2.2.1 (SHIMADZU, Japan). An
ofﬂine automatic sample applicator equipped with 100 lL syr-
inge (Camag Linomat 5, Switzerland) and a TLC scanner (Ca-
mag, Switzerland) were employed for preparation and
measurement of TLC plates, respectively. Both of the scanner
and the densitometer were controlled using winCATS soft-
ware. A UV lamp with short wavelength 254.0 nm (Vilber
Lourmat, MARN´E LA VALLEE Cedex 1, France) was used
for visualization of TLC plates.
Pure drugs and samples
EZB and ATVC pure standards were kindly supplied by Mar-
cyrl Pharmaceutical Industries, El-Obour City, Egypt. Their
purity were found to be 99.85% and 100.35%, respectively,
according to the absorptivity values reported [4,5]. Samples
of Atoreza tablets (Marcyrl); batch no. 1030599, labeled to
contain 10 mg Ezetimibe and 10 mg Atorvastatin, per tablet
were obtained from the market.
Chemicals, reagents and standard solutions
All chemicals used throughout this work were of analytical
grade, and solvents were of spectroscopic grade. TLC plates
(20 · 20 cm) pre-coated with silica gel 60F254 were obtained
from Merck, Germany. EZB and ATVC stock solutions
(1 mg mL1) were prepared by weighing accurately 100 mg
of each powder into two separate 100-mL volumetric ﬂasks.
Methanol (50 mL) was added, shaken for a few minutes and
completed to volume with the same solvent. Working solutions
(100 lg mL1 in methanol) were prepared by accurately trans-
ferring 10 mL of the stock solution of EZB and 10 mL of the
stock solution of ATVC in two separate 100-mL measuring
ﬂasks and diluting to the mark with methanol. A set of
Spectro & densito of Ezetimibe and Atorvastatin 53laboratory prepared mixtures of different ratios (1:1, 1:1.5,
1.5:1, 1:2 and 2:1) were prepared by transferring different vol-
umes of each of EZB and ATVC stock solutions into 10-ml
volumetric ﬂasks and diluting to volume with methanol.ig. 2 Zero order absorption spectra of 20 lg mL1 of Ezetim-
e (––), 20 lg mL1 of Atorvastatin calcium (- - -) and a (1:1)
ixture contains10 lg mL1 of each (  ) using methanol as a
lank.Procedures
Construction of calibration curve for D1 spectrophotometric
method
Different aliquots equivalent to 100.00–300.00 lg of EZB and
100.00–350.00 lg of ATVC working solutions (100 lg mL1 in
methanol) were accurately transferred into a series of 10-mL
volumetric ﬂasks then diluted to volume using methanol. D1
spectra were recorded at Dk= 4 and scaling factor = 10 using
methanol as a blank. Calibration curves were obtained by plot-
ting the peak amplitude at 223.8 and 233.0 nm versus the cor-
responding concentration of EZB and ATVC, respectively.
Construction of calibration curve for D2 spectrophotometric
method
Aliquots of ATVC working solution (100 lg mL1 in metha-
nol) equivalent to 100.00–350.00 lg were accurately transferred
into a series of 10-mL volumetric ﬂasks. The volume was com-
pleted to the mark with methanol and the D2 spectra were re-
corded against methanol as a blank at Dk= 8 and scaling
factor = 1000. Calibration curve was obtained by plotting
the peak amplitude at 313.0 nm (corresponding to zero-cross-
ing of EZB) versus the corresponding concentration of ATVC.
Construction of calibration curve for IS spectrophotometric
method
Into two separate sets of 10-mL volumetric ﬂasks, aliquots
equivalent to 100.00–350.00 lg and 50.00–300.00 lg of EZB
were transferred from their working solution (100 lg mL1
in methanol) and the volume was completed with methanol.
Calibration curves were obtained by plotting the peak ampli-
tude at 224.6 nm and 238.6 versus the corresponding concen-
tration of EZB.
Optimization of TLC-densitometric separation parameters
A laboratory prepared mixture of EZB and ATVC (1:1 ratio,
0.2 lg band1) used to investigate the optimum separation
conditions. Developing systems of different composition and
ratios were tried: chloroform–ethyl acetate (8:2, v/v), chloro-
form–acetone (7:3, v/v), Toluene–methanol (6:4, v/v), and
diethyl ether–acetonitrile (8:2, v/v). Various band dimensions
were tested in order to obtain sharp and symmetrical peaks.
Plates were scanned at different wavelengths: 232.0 nm,
246.0 nm, and 266.0 nm) and using different slit dimensions.
Optimum set of instrumental parameters were employed for
measurement of all plates in future experiments.
Construction of calibration curve for TLC-densitometric method
For preparation of a calibration plot, 1, 2, . . . , 6 lL of stan-
dard working solutions of ATVC and EZB (100 lg mL1)were spotted as bands of 6 mm width on TLC plates
(20 · 10 cm). Bands were applied at 5 mm interval and
15 mm from the bottom and sides. Linear ascending plate
development to a distance of 8 cm was performed in a suitable
chromatographic tank previously saturated for 1 h with the
developing mobile phase (diethyl ether–ethyl acetate; 7:3, v/
v) at room temperature. The peak area was recorded at a scan-
ning wavelength of 254.0 nm. Calibration curves were con-
structed by plotting the integrated peak area versus the
corresponding concentrations of each drug and regression
equation parameters were computed.
Application to pharmaceutical formulations
A total of ten Atoreza tablets were accurately weighed and
crushed to a ﬁne powder. An amount equivalent to one tablet
(containing10 mg of EZB and 10 mg of ATVC) was taken, ex-
tracted using 30 mL of methanol using a magnetic stirrer for
30 min. The mixture was transferred into a 100 mL volumetric
ﬂask through a Whatman No. 10 ﬁlter paper (pore si-
ze = 11 lm). The residue was washed twice with methanol
and the combined ﬁltrate and washings were made up to the
mark with methanol to a ﬁnal concentration of 100 lg mL1
of each drug. A suitably diluted sample was measured as men-
tioned under each method. The possibility of interference from
dosage form additives to assay performance was investigated
using the standard addition technique.
Results and discussion
Analytical methods for the determination of binary mixture
without previous separation are of interest to quality control
(QC) labs and national regulatory authorities (NRA) around
the world. The absorption spectra of EZB and ATVC show se-
vere overlap (Fig. 2) that makes their simultaneous determina-
tion difﬁcult. In this work, our main task was to develop
simple, sensitive and accurate analytical methods for the deter-
mination of EZB and ATVC in their binary mixture and phar-
maceutical formulation with satisfactory precision for goodF
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m
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Fig. 3 First derivative absorption spectra of 20 lg mL1 of
Ezetimibe (––) and 20 lg mL1 of Atorvastatin calcium (  ) using
methanol as a blank.
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D1 spectrophotometric method
Derivative spectrophotometry offers greater selectivity than
does normal spectrophotometry as it decreases spectral
overlap and allows better resolution. First derivative (D1)
spectrophotometric technique was used to resolve spectral
overlapping of the absorption spectra of EZB and ATVC.
Upon applying (D1) technique, EZB and ATVC could be deter-
mined by measuring peak amplitude of D1 spectra at 223.8 nm
(corresponding to zero-crossing of ATVC) and 233.0 nm
(corresponding to zero-crossing of EZB) respectively (Fig. 3).
A linear correlation was obtained between peak amplitude
and the corresponding concentration in the range of 10.00–
30.00 lg mL1 for EZB and in the range of 10.00–35.00
lg mL1 for ATVC. Regression equations were computed
and various regression parameters are summarized in Table 1.
PA ¼ 0:017Cþ 0:0219 r ¼ 0:9995 at 223:8 nm for EZB
PA ¼ 0:006C 0:0012 r ¼ 0:9998 at 233:0 nm for ATVC
where PA is peak amplitude, C is the concentration in
lg mL1 and r is the correlation coefﬁcient. The proposed
method was found valid for the simultaneous determination
of EZB and ATVC in different laboratory prepared mixtures
with mean percentage recoveries of 99.66 ± 1.03 and
99.39 ± 0.81, respectively, as represented in Table 2. The sug-
gested method has been applied to assay EZB and ATVC in
Atoreza tablets and its validity was further assessed by
applying the standard addition technique, Table 3.
D2 spectrophotometric method
D2 spectrophotometric technique was also used to resolve
spectral overlapping of the absorption spectra of EZB and
ATVC, Fig. 4. Upon applying D2 technique, ATVC could be
determined by measuring peak amplitude of D2 spectrum at
313.0 nm (corresponding to zero-crossing of EZB). A linearcorrelation was obtained between peak amplitude and the cor-
responding concentration in the range of 10.00–35.00 lg mL1
for ATVC. Regression equation was computed and various
regression parameters are summarized in Table 1.
PA ¼ 0:0349C 0:0047 r ¼ 0:9994 at 313:0 nm
where PA is peak amplitude at 313.0 nm, C is the concentra-
tion in lg mL1 and r is the correlation coefﬁcient. The pro-
posed method is valid for determination of ATVC in presence
of EZB in different laboratory prepared mixtures with mean
percentage recoveries of 100.47 ± 1.06 as represented in Table
2. The suggested method has been applied to assay ATVC in
Atoreza tablets, and its validity was further assessed by apply-
ing the standard addition technique, Table 3. The D2 method
failed to determine EZB in the presence of ATVC. Thus, total
concentration was determined using the below IS method.
Then, EZB concentration was determined mathematically.
IS spectrophotometric method
Erram and Tipnis [20] developed the isosbestic spectrophoto-
metric method. At the isosbestic point the mixture of drugs
acts as a single component and gives the same absorbance as
pure drug. In this mixture, the absorbance value at the isos-
bestic points 224.6 nm (Aiso1) and 238.6 nm (Aiso2) was
determined (Fig. 2) and the total concentration of both drugs
was calculated. Since the concentration of ATVC in this mix-
ture can be measured using D2 spectroscopy at 313.0 nm, the
concentration of EZB could be calculated by subtraction. A
linear correlation was obtained between the absorbance values
and the corresponding drug concentrations. Regression equa-
tions were computed and various regression parameters are
summarized in Table 1.
Aiso1 ¼ 0:0365Cþ 0:0137 r ¼ 0:9995 at 224:6 nm
Aiso2 ¼ 0:043Cþ 0:0316 r ¼ 0:9997 at 238:6 nm
where A is the absorbance, C is the total concentration of both
drugs in lg mL1 and r is the correlation coefﬁcient. The pro-
posed methods were found valid for the determination of EZB
in laboratory prepared mixtures with mean percentage recov-
eries of 100.89 ± 0.89 and 100.47 ± 0.81 as represented in Ta-
ble 2. The proposed methods were successfully applied for the
analysis of both drugs in pharmaceutical dosage form and the
results are shown in Table 3.TLC-densitometric method
TLC-densitometry is a useful technique for the qualitative and
quantitative determination of drug mixtures. This technique of-
fers a simple approach to quantify separated drugs directly on
TLC plates via measuring band optical densities. The amount
of each compound is determined by comparison to a standard
curve prepared using a reference material and chromato-
graphed under the same condition [21]. In this work, TLC-den-
sitometric method showed low limits of detection and
quantitation. To improve separation of bands, it was necessary
to investigate the effect of different experimental variables.
Reported TLC-densitometric methods for the simultaneous
determination of EZB/ATVC mixture employed different mo-
bile phases [5,11–13]. Most of the reported mobile phases were
Table 1 Results of assay validation parameters obtained by applying the proposed methods.
Parameter Ezetimibe Atorvastatin calcium
IS
D1 224.6 nm 238.6 nm TLC-densitometry D1 D2 TLC-densitometry
Concentration range 10.00–30.00 (lg mL1) 10.00–35.00 (lg mL1) 5.00–30.00 (lg mL1) 0.10–0.60 (lg band1) 10.00–35.00 (lg mL1) 10.00–35.00 (lg mL1) 0.10–0.60 (lg band1)
Linearity
Slope 0.0170 0.0365 0.0430 4656.6857 0.0060 0.0349 5165.4857
Intercept 0.0219 0.0137 0.0316 190.7733 0.0012 0.0047 76.7133
Correlation coeﬃcient (r) 0.9995 0.9995 0.9997 0.9998 0.9998 0.9994 0.9999
Standard error of the slope 0.0003 0.0006 0.0005 42.5386 0.00005 0.0006 33.3275
Conﬁdence limit of the slope 0.0170 ± 0.0008 0.0365 ± 0.0016 0.0430 ± 0.0014 4656.6857 ± 118.1060 0.0060 ± 0.0002 0.0349 ± 0.0017 5165.4857 ± 92.5321
Standard error of the intercept 0.0057 0.0140 0.0095 16.5664 0.0013 0.0144 12.9792
Conﬁdence limit of the intercept 0.0219 ± 0.0158 0.0137 ± 0.0389 0.0316 ± 0.0265 190.7733 ± 45.9957 0.0012 ± 0.0036 0.0047 ± 0.0399 76.7133 ± 36.0361
Accuracy (Mean ± S.D.) 100.23 ± 1.62 99.75 ± 1.43 99.80 ± 0.95 99.77 ± 1.30 99.58 ± 0.84 99.72 ± 1.36 99.86 ± 0.97
Precision (RSD %)
Repeatabiltya 0.96 0.45 0.48 1.00 1.24 1.14 0.97
Intermediate precisionb 1.16 1.31 1.10 1.40 1.32 1.34 1.29
Speciﬁcity 99.66 ± 1.03 100.89 ± 0.89 100.47 ± 0.81 100.25 ± 0.82 99.39 ± 0.81 100.47 ± 1.06 100.49 ± 0.78
Limit of detection (LOD)c 2.70 lg mL1 3.10 lg mL1 1.79 lg mL1 0.03 lg band1 1.75 lg mL1 3.33 lg mL1 0.02 lg band1
Limit of quantitation (LOQ)c 8.19 lg mL1 9.41 lg mL1 5.43 lg mL1 0.09 lg band1 5.31 lg mL1 10.09 lg mL1 0.06 lg band1
LOD= (SD of the response/slope) · 3.3; LOQ= (SD of the response/slope) · 10.
a The intraday (n= 3), average of three concentrations repeated three times within day.
b The interday (n= 3), average of three different concentrations repeated three times in three successive days.
c Limits of detection and quantitation are determined via calculations.
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Table 2 Determination of Ezetimibe and Atorvastatin calcium in laboratory prepared mixtures by the proposed spectrophotometric methods and the reported method.
Mixture no. Ezetimibe recovery %a Atorvastatin calcium recovery %a
Claimed taken (lg mL1) IS
Atorvastatin Ezetimibe D1 224.6 nm 238.6 nm Reported methodb D1 D2 Reported methodb
1 10 10 98.88 99.67 100.86 100.85 100.33 98.77 100.4
2 10 15 100.43 101.82 99.86 99.91 98.67 100.77 100.07
3 10 20 98.27 101.7 101.61 101.68 98.67 101.06 98.6
4 15 10 100.65 100.7 100.45 100.1 99.11 100.23 99.4
5 20 10 100.06 100.58 99.59 100.57 100.17 101.53 98.18
Mean ± S.D. 99.66 ± 1.03 100.89 ± 0.89 100.47 ± 0.81 100.62 ± 0.70 99.39 ± 0.81 100.47 ± 1.06 99.33 ± 0.94
a Average of three determinations.
b Absorbance ratio method (Q-analysis) at 238.6 nm (iso-absorptive point) and 232.6 nm (kmax of Ezetimibe) [3].
Table 3 Determination of Ezetimibe and Atorvastatin calcium in Atoreza tablets by the proposed methods and application of standard addition technique.
D1 IS TLC-densitometry
224.6 nm 238.6 nm
Product Recoverya
% ±S.D.
Added
lg mL1
Founda
lg mL1
Recovery % Recoverya %
±S.D.
Added
lg mL1
Founda
lg mL1
Recovery
%
Recoverya %
±S.D.
Added
lg mL1
Founda
lg mL1
Recovery % Recoverya
% ±S.D.
Added
lg band1
Founda
lg band1
Recovery %
Ezetimibe in
Atoreza tablets
(Batch No. 1030599).
100.02 ± 1.29 101.05 ± 1.63 99.03 ± 0.91 100.44 ± 1.26
5 5.06 101.2 8 8.05 100.63 8 8.15 101.88 0.1 0.102 102
10 9.94 99.4 10 9.92 99.2 10 9.94 99.4 0.2 0.201 100.5
15 15.23 101.53 12 12.23 101.92 12 11.84 98.67 0.4 0.407 101.75
Mean ± S.D. 100.71 ± 1.15 100.58 ± 1.36 99.98 ± 1.68 101.42 ± 0.80
D1 D2 TLC-densitometry
Product Recoverya
% ±S.D.
Added
lg mL1
Founda
lg mL1
Recovery % Recoverya %
±S.D.
Added
lg mL1
Founda
lg mL1
Recovery % Recoverya %
±S.D.
Added
lg band1
Founda
lg band1
Recovery %
Atorvastatin calcium
in Atoreza tablets
(Batch No. 1030599).
99.48 ± 0.82 5.00 5.00 100.00 100.46 ± 0.83 8.00 7.88 98.50 100.14 ± 1.02 0.10 0.101 101.00
10.00 10.17 101.70 10.00 10.09 100.90 0.20 0.203 101.50
15.00 15.00 100.00 12.00 11.86 98.83 0.40 0.400 100.00
Mean ± S.D. 100.57 ± 0.98 99.41 ± 1.30 100.83 ± 0.76
a Average of three determinations
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Fig. 4 Second derivative absorption spectra of 20 lg mL1 of
Ezetimibe (––) and 20 lg mL1 of Atorvastatin calcium (  ) using
methanol as a blank.
Spectro & densito of Ezetimibe and Atorvastatin 57of relatively complex composition. When a two-component
mobile phase was employed, insufﬁcient validation was carried
out and no system suitability data was calculated [12]. Thus the
aim of this TLC-densitometric work was to investigate the use
of new, simple, two component only mobile phase. Different
developing systems of different composition and ratios were
tried for separation and results were evaluated with respect
to efﬁciency of separation and the shape of separated bands.
The optimum mobile phase composition was found to be
diethyl ether–ethyl acetate (7:3, v/v). This mobile phase al-
lowed good separation between the binary mixtures with good
Rf values without tailing of the separated bands (Fig. 5). Dif-
ferent band dimensions were tested in order to obtain sharp,Fig. 5 Thin layer chromatogram of separated peaks of 0.2 lg band1
(1:1) mixture contains 0.2 lg band1 of each (c) using diethyl ether: etsymmetrical and well resolved peaks. The optimum band
width was chosen (6 mm) and the inter-space between bands
was found to be 5 mm. Different scanning wavelengths were
tried where 254 nm was found optimum for both drugs.
Scanned peaks were sharp, symmetrical and minimum noise
was noticed. Moreover, at this wavelength maximum sensitiv-
ity was obtained for both drugs. The slit dimensions of the
scanning light beam should ensure complete coverage of band
dimensions on the scanned track without interference of adja-
cent bands. Different slit dimensions were tried, where
6 mm · 0.3 mm proved to be the slit dimension of choice which
provides highest sensitivity (results not shown).
Calibration curves were constructed by plotting the inte-
grated peak area versus the corresponding concentrations in
the range of 0.10–0.60 lg band1 for both EZB and ATVC.
The concentration of EZB and ATVC were calculated from
the following regression equations. Regression equation
parameters are summarized in Table 1.
For EZB; Y1 ¼ 4656:6857C1  190:7733 r1 ¼ 0:9998
For ATVC; Y2 ¼ 5165:4857C2 þ 76:7133 r2 ¼ 0:9999
where Y1 and Y2 are the integrated peak area of EZB and
ATVC, respectively, C1 and C2 are the concentration of EZB
and ATVC in lg band1, respectively, and r1 and r2 are the
correlation coefﬁcients of EZB and ATVC, respectively.
Various validation parameters are summarized in Table 1.
The validity of the proposed methods was assessed by applying
the standard addition technique. Results obtained were repro-
ducible with low relative standard deviation as shown in Table
3. Various separation parameters; resolution (Rs), peak sym-
metry, capacity factor (K0) and selectivity factor (a) were calcu-
lated using a (1:1) mixture contains 0.2 lg band1 of each drug
and ATVC as reference. Resolution and selectivity were found
to be 10.46 and 27.32, respectively. Peak symmetry factor was
found to be 0.71 and 0.94 while capacity factor was 10.11 and
0.37 for ATVC and EZB, respectively.of Ezetimibe (a), 0.2 lg band1 of Atorvastatin calcium (b), and a
hyl acetate (7:3, by volume) as a mobile phase.
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58 Y.Z. Baghdady et al.Statistical comparison to reported method
A statistical comparison of the results obtained by the three
proposed methods and the reported method [3] was carried
out. The values of the calculated t and F were found smaller
than the tabulated ones. This proved that there is no signiﬁcant
difference between the proposed methods and the reported
method with respect to accuracy and precision. Results are
summarized in Table 4.Conclusion
Three new selective and sensitive methods for the simultaneous
determination of EZB and ATVC were developed. The D1, D2,
IS spectrophotometric, and TLC-densitometric method were
applied for the simultaneous determination of EZB and ATVC
either in their bulk powder form or in their pharmaceutical for-
mulations. Results demonstrated the lack of interference from
dosage form additives and the usefulness of the methods. All
methods are simple, sensitive, precise, accurate, inexpensive
and non polluting to environment. Methods are suitable for
routine quality control analysis of EZB and ATVC in pharma-
ceutical preparations.References
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